Login to Your Account

Blisibimod Misses PEARL-SC Endpoint; Anthera Plummets

By Marie Powers
Staff Writer

Friday, June 29, 2012
Shares of Anthera Pharmaceuticals Inc. struggled to find a floor Thursday after the company reported following the market's close Wednesday afternoon that its Phase IIb PEARL-SC study of blisibimod in systemic lupus erythematosus (SLE) failed to meet the primary efficacy endpoint – clinical improvement at 24 weeks in the SLE responder index for the pooled blisibimod dose groups – due to lack of efficacy in two low-dose groups.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription